Biochemical and structural analysis of the binding determinants of a vascular endothelial growth factor receptor peptidic antagonist.
Cyclic peptide antagonist c[YYDEGLEE]-NH(2), which disrupts the interaction between vascular endothelial growth factor (VEGF) and its receptors (VEGFRs), represents a promising tool in the fight against cancer and age-related macular degeneration. Furthermore, coupled to a cyclen derivative, this ligand could be used as a medicinal imaging agent. Nevertheless, before generating such molecular probes, some preliminary studies need to be undertaken in order to define the more suitable positions for introduction of the cyclen macrocycle. Through an Ala-scan study on this peptide, we identified its binding motif, and an NMR study highlights its binding sites on the VEGFR-1D2 Ig-like domain. Guided by the structural relationship results deduced from the effect of the peptides on endothelial cells, new peptides were synthesized and grafted on beads. Used in a pull-down assay, these new peptides trap the VEGFRs, thus confirming that the identified amino acid positions are suitable for further derivatization.
Gautier
Benoit
B
Université Paris Descartes, UFR Biomédicale, Laboratoire de Pharmacochimie Moléculaire et Cellulaire, INSERM U648, 75006 Paris, France.
Goncalves
Victor
V
Diana
Donatella
D
Di Stasi
Rossella
R
Teillet
Florence
F
Lenoir
Christine
C
Huguenot
Florent
F
Garbay
Christiane
C
Fattorusso
Roberto
R
D'Andrea
Luca Domenico
LD
Vidal
Michel
M
Inguimbert
Nicolas
N
D000595:Amino Acid Sequence; D000818:Animals; D001665:Binding Sites; D000080027:Cyclams; D006571:Heterocyclic Compounds / Q000737:chemistry; D006801:Humans; D008163:Luminescent Measurements; D008239:Lysine; D009682:Magnetic Resonance Spectroscopy; D008958:Models, Molecular; D057054:Molecular Imaging; D015335:Molecular Probes / Q000737:chemistry / Q000378:metabolism / Q000494:pharmacology; D010456:Peptides, Cyclic / Q000737:chemistry* / Q000378:metabolism* / Q000494:pharmacology; D010766:Phosphorylation / Q000187:drug effects; D011485:Protein Binding; D011487:Protein Conformation; D040262:Receptors, Vascular Endothelial Growth Factor / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000378:metabolism*; D015398:Signal Transduction / Q000187:drug effects; D013329:Structure-Activity Relationship; D013379:Substrate Specificity; D040281:Vascular Endothelial Growth Factor Receptor-1 / Q000037:antagonists & inhibitors / Q000378:metabolism; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000037:antagonists & inhibitors / Q000378:metabolism
D000080027:Cyclams; D006571:Heterocyclic Compounds; D015335:Molecular Probes; D010456:Peptides, Cyclic; C038072:cyclen; D040262:Receptors, Vascular Endothelial Growth Factor; D040281:Vascular Endothelial Growth Factor Receptor-1; D040301:Vascular Endothelial Growth Factor Receptor-2; D008239:Lysine